kabutan

ReproCELL Incorporated(4978) Summary

4978
TSE Growth
ReproCELL Incorporated
159
JPY
-4
(-2.45%)
Jan 29, 3:12 pm JST
1.03
USD
Jan 29, 1:12 am EST
Result
PTS
outside of trading hours
159.4
Jan 29, 3:12 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.74
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
163 JPY 1.06 USD
Previous Close Jan 28
163 JPY 1.06 USD
High Jan 29, 9:00 am
163 JPY 1.06 USD
Low Jan 29, 10:20 am
156 JPY 1.02 USD
Volume
867,200
Trading Value
0.14B JPY 0.90M USD
VWAP
158.76 JPY 1.04 USD
Minimum Trading Value
15,900 JPY 103 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
398
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
1,039
1-Year High Feb 6, 2025
31,812
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 6,119,800
Jan 16, 2026 0 5,403,000
Jan 9, 2026 0 4,942,400
Dec 26, 2025 0 5,165,100
Dec 19, 2025 0 5,330,300
Company Profile
ReproCELL Incorporated is a biotech venture company specializing in iPS cell-related research reagents, collaborating with the University of Tokyo and Kyoto University. The company also offers contract manufacturing services.
Sector
Chemicals
ReproCELL Incorporated develops businesses centered on iPS cell-related technologies. In its research support division, the company manufactures and sells research products, provides research outsourcing services, and distributes cell measurement equipment. The medical division focuses on regenerative medicine research and development, contract manufacturing of iPS cell regenerative medicine products, and clinical testing services. Currently, ReproCELL is developing three regenerative medicine products: StemCaimal, iPS neural glial cells, and tumor-infiltrating lymphocyte infusion therapy. The company's strength lies in its RNA reprogramming technology, which enables the creation of highly safe iPS cells.